Robert Avery
Ophthalmology · Albuquerque, NMNPI 1871509570
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,797 of the $4,592 with a category attached, or 60.9%. Alcon accounts for 70.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $1,716 and has fallen 69.2% since, to $528 in 2025.
Across 41 payments — averaging $112.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$233
- Astellas Pharma US Inc$201
- Bausch & Lomb Americas Inc.$183
- Eyepoint US, Inc.$169
- Glaukos Corporation$132
- plus $460 from 8 others
Across 1 payment — averaging $444.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$445
What the payments were for
- Travel & lodging$1,79539%
- Food & beverage$2,79761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 17 | $3,215 |
| AbbVie | 2 | $233 |
| Astellas Pharma US Inc | 3 | $201 |
| Bausch & Lomb Americas Inc. | 5 | $183 |
| Eyepoint US, Inc. | 2 | $169 |
| Glaukos Corporation | 1 | $132 |
| Genentech USA, Inc. | 1 | $120 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $93 |
| Ocular Therapeutix, Inc. | 2 | $71 |
| Genentech, Inc. | 1 | $55 |
| Shire North American Group Inc | 2 | $48 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,592 in reported general payments places this provider in the 80th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $15,468 |
| RhopressaNetarsudil Mesylate | 29 | $12,251 |
| Prednisolone Acetate | 258 | $8,573 |
| Cyclosporine | 15 | $6,901 |
| Latanoprost | 372 | $6,737 |
| LumiganBimatoprost | 16 | $5,834 |
| Travoprost | 33 | $3,891 |
| Timolol Maleate | 186 | $3,214 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 136 | $2,323 |
| Brimonidine Tartrate | 83 | $1,185 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 57 | $985 |
| ErythromycinErythromycin Base | 47 | $793 |
| Dorzolamide Hcl | 41 | $775 |
| Doxycycline Hyclate | 16 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $233 | $21,30129 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $17 | $12,25129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Albuquerque
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
- Iuri GolubevAlbuquerque$7K
- Thomas GilletteAlbuquerque$6K
- Kenneth DownesAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.